Disc Medicine, Inc. (NASDAQ:IRON) Financings
Financings
| Raise | Date |
|---|---|
| Public offering of common stock Made bigger: US$450M · US$75 a share · Jefferies +6 Dealers: Jefferies (co-lead), Leerink Partners (co-lead), Morgan Stanley (co-lead), Cantor (co-lead), LifeSci Capital, BMO Capital Markets, H.C. Wainwright & Co. Use of proceeds: Fund research and clinical development, support potential commercialization of bitopertin for EPP and XLP, pre-commercialization activities, working capital | Oct 21, 2026 |
| Public offering of common stock and pre-funded warrants Made bigger: about US$225M · US$84 a share · Jefferies +5 Dealers: Jefferies (co-lead), Leerink Partners (co-lead), Morgan Stanley (co-lead), Cantor (co-lead), Wedbush PacGrow, H.C. Wainwright & Co. Use of proceeds: Support potential commercialization of bitopertin for EPP and XLP, fund research and clinical development, working capital and general corporate purposes | Oct 21, 2025 |
| Public offering of common stock and pre-funded warrants Made bigger: about US$225.5M · US$55 a share · Jefferies +7 Dealers: Jefferies (co-lead), Leerink Partners (co-lead), Stifel (co-lead), Cantor (co-lead), BMO Capital Markets, LifeSci Capital, Wedbush PacGrow, H.C. Wainwright & Co. Use of proceeds: Research and clinical development of product candidates, potential commercialization of bitopertin for EPP and XLP, working capital and general corporate purposes | Jan 22, 2025 |